Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
61-75 of 3960 results
Sun Pharma, Technion to develop new class of oncology drugs
By PBR Staff Writer
India-based Sun Pharmaceutical Industries and Israel's Technion University have entered into an exclusive worldwide research and license agreement for the development of new class of oncology drugs.
Drug Research > Drug Discovery & Development > News
Reata gets FDA orphan drug status for bardoxolone methyl to treat PAH
By PBR Staff Writer
Reata Pharmaceuticals, a US-based developer of breakthrough medicines, has secured orphan drug designation from the FDA Office of Orphan Products Development (OOPD) for bardoxolone methyl to treat pulmonary arterial hypertension (PAH).
Drug Research > Drug Discovery & Development > News
US FDA modifies partial clinical hold on Tekmira's TKM-Ebola IND application
By PBR Staff Writer
The US Food and Drug Administration (FDA) has notified Tekmira Pharmaceuticals that the partial clinical hold on its investigational new drug (IND) application for TKM-Ebola, an anti-Ebola virus RNAi therapeutic, has been modified to permit repeat dosing of healthy volunteers at a dose of 0.24 mg/kg/day.
Drug Research > Drug Discovery & Development > News
Eisai, Genomics to analyse large-scale genotype data to inform drug development
By PBR Staff Writer
Japanese pharmaceutical firm Eisai and UK-based genome analytics firm Genomics have entered into collaboration agreement to use the latter’s statistical in analyses of large-scale genotype/phenotype data to inform Eisai’s drug development.
Drug Research > Drug Discovery & Development > News
Bristol-Myers, uniQure enter cardiovascular gene therapy deal
By PBR Staff Writer
Bristol-Myers Squibb (BMS) and Netherlands-based uniQure have entered into exclusive strategic collaboration to develop gene therapies for cardiovascular diseases.
Drug Research > Drug Discovery & Development > News
BIND extends deal with Pfizer to develop and commercialize multiple Accurins
By PBR Staff Writer
Us-based BIND Therapeutics has extended the terms of its global collaboration with Pfizer to create Accurins that optimize the therapeutic potential of two molecularly targeted oncology drugs in Pfizer’s pipeline.
Drug Research > Drug Discovery & Development > News
Schrödinger, Sanofi sign $120m drug discovery deal
By PBR Staff Writer
US-based computational drug designer Schrödinger has entered into a multi-year early drug discovery collaboration with Sanofi in which Schrödinger will offer target analysis and validation to lead identification and lead optimization for as many as ten drug discovery programs.
Drug Research > Drug Discovery & Development > News
Astellas, MD Anderson to develop new drugs to treat AML
By PBR Staff Writer
Japan-based Astellas Pharma and the University of Texas MD Anderson Cancer Center have signed an option agreement to research and develop a new monoclonal antibody drug to treat patients with acute myeloid leukemia (AML).
Drug Research > Drug Discovery & Development > News
Intrexon, Merck ink deal to develop and commercialize CAR-T cancer therapy
By PBR Staff Writer
US-based Intrexon and Merck Serono have entered into an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies.
Drug Research > Drug Discovery & Development > News
Horizon to buy Hyperion Therapeutics for $1.1bn
By PBR Staff Writer
Irish pharmaceutical firm Horizon Pharma has entered into an agreement to acquire all of the issued and outstanding shares of US-based Hyperion Therapeutics for about $1.1bn.
Drug Research > Drug Discovery & Development > News
Zogenix begins dosing in Phase Ib Relday multi-dose clinical trial to treat schizophrenia
By PBR Staff Writer
US-based pharmaceutical firm Zogenix has started dosing patients in its multi-dose Phase Ib clinical trial of Relday, a proprietary, long-acting, subcutaneously injected formulation of risperidone being investigated to treat schizophrenia.
Drug Research > Drug Discovery & Development > News
Mast Therapeutics to develop vepoloxamer to treat chronic heart failure
By PBR Staff Writer
US-based biopharmaceutical firm Mast Therapeutics is planning to develop vepoloxamer (MST-188) to treat patients with chronic heart failure.
Drug Research > Drug Discovery & Development > News
Lilly partners with China's Innovent for new oncology therapies
By PBR Staff Writer
Eli Lilly and Company and China-based biopharmaceutical firm Innovent Biologics have collaborated to create possible new treatment options for cancer patients in China and around the world.
Drug Research > Drug Discovery & Development > News
AbbVie enters into license deal with C2N Diagnostics for Alzheimer's disease therapy
By PBR Staff Writer
US-based AbbVie and C2N Diagnostics, a protein diagnostic and therapeutic discovery firm, have collaborated for the development and commercialization of a portfolio of anti-tau antibodies to treat Alzheimer's disease (AD) and other neurological disorders.
Drug Research > Drug Discovery & Development > News
Lilly, Hanmi to develop BTK inhibitor to treat autoimmune diseases
By PBR Staff Writer
Eli Lilly and Company has entered into an exclusive license and collaboration agreement with Hanmi Pharmaceutical to develop and commercialize the latter's oral Bruton's tyrosine kinase (BTK) inhibitor, HM71224, to treat autoimmune and other diseases.
Drug Research > Drug Discovery & Development > News
61-75 of 3960 results